Saisheng Pharmaceutical (06600): 286,400 share options have been exercised
According to the Zhitong Finance App, Saisheng Pharmaceutical (06600) announced that on April 26, 2024, the 286,400 share options granted under the company's initial public offering after-sales share option plan have been exercised in accordance with the rules of the initial public offering after-sales share option plan.
Saisheng Pharmaceutical (06600): 7,500 share options have been exercised
Saisheng Pharmaceutical (06600) issued an announcement. On April 23, 2024, the company's initial public offering of after-sales share purchase options...
Saisheng Pharmaceutical (06600): 90,000 share options exercised
Saisheng Pharmaceutical (06600) announced that on April 22, 2024, the company will publicly launch an after-sales share purchase plan project for the first time...
Saisheng Pharmaceutical (06600): 60,600 share options have been exercised
According to the Zhitong Finance App, Saisheng Pharmaceutical (06600) announced that on April 19, 2024, according to the rules of the initial public offering after-sales share option plan, the 86,400 share options granted under the initial public offering after-sales share option plan have expired; and the 60,600 share options granted under the initial public offering after-sales share option plan have been exercised.
Saisheng Pharmaceutical announced that 180,000 share options have been granted and have been exercised
Saisheng Pharmaceutical (06600) announced that on April 18, 2024, according to the rules of the initial public offering after-sales share option plan: 7.167.36 million share options granted under the initial public offering after-sales share option plan have been vested; 706.84 million share options granted under the initial public offering after-sales share option plan have expired; and 180,000 share options granted under the initial public offering after-sales share option plan have been exercised.
Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31
Sciclone Pharmaceuticals (Holdings) (HKG:6600) sought an extension for the dispatch of the scheme document related to its privatization as it needs more time to finalize the document's content. The bi
Saisheng Pharmaceutical announced the exercise of 10,000 share options
Saisheng Pharmaceutical (06600) announced that on April 15, 2024, 10,000 share options granted under the company's initial public offering after-sales share option plan have been exercised in accordance with the rules of the initial public offering after-sales share option plan.
Saisheng Pharmaceutical (06600): 10,000 share options exercised
Saisheng Pharmaceutical (06600) issued an announcement. On April 15, 2024, the company's initial public offering of after-sales share purchase options...
Saisheng Pharmaceutical announced that a total of 308,500 share options have been exercised
Saisheng Pharmaceutical (06600) announced that on April 12, 2024, 254,000 share options granted under the company's share purchase incentive plan (granting holders 254,000 existing shares) and 54,000 share options granted under the initial public offering after-sales share option plan have been exercised in accordance with the rules of the share purchase incentive plan and the initial public offering after-sales share option plan, respectively.
Saisheng Pharmaceutical (06600): A total of 308,500 share options have been exercised
Saisheng Pharmaceutical (06600) issued an announcement. On April 12, 2024, the company's share purchase incentive plan (granting holding...
Saisheng Pharmaceutical: A total of 51,800 share options have been exercised
Saisheng Pharmaceutical (06600) announced that on April 8, 2024, 20,000 share options granted under the company's share purchase incentive plan (granting holders 20,000 existing shares) and 31,800 share options granted under the initial public offering after-sales share option plan have been exercised in accordance with the rules of the share option incentive plan and the initial public offering after-sales share option plan, respectively.
Saisheng Pharmaceutical (06600): A total of 51,800 share options have been exercised
According to Zhitong Finance App, Saisheng Pharmaceutical (06600) announced that on April 8, 2024, 20,000 share options granted under the company's share option incentive plan (granting holders 20,000 existing shares) and 31,800 share options granted under the initial public offering after-sales share option plan have been exercised in accordance with the rules of the share option incentive plan and the initial public offering after-sales share option plan, respectively.
Saisheng Pharmaceutical (06600): 277.4 million share options exercised
Saisheng Pharmaceutical (06600) announced that on April 3, 2024, the company's initial public offering under the after-sales share purchase plan...
Saisheng Pharmaceutical announced that 42,000 share options have been exercised
Saisheng Pharmaceutical (06600) announced that on April 2, 2024, 42,000 share options granted under the company's initial public offering after-sales share option plan have been exercised in accordance with the rules of the initial public offering after-sales share option plan.
Is SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) Latest Stock Performance A Reflection Of Its Financial Health?
SciClone Pharmaceuticals (Holdings)'s (HKG:6600) stock is up by a considerable 35% over the past month. Given that the market rewards strong financials in the long-term, we wonder if that is the cas
Saisheng Pharmaceutical (06600): 42,000 share options have been exercised
Saisheng Pharmaceutical (06600) announced that on April 2, 2024, the company's initial public offering of an after-sales share purchase plan...
Beishui Trends | Beishui Transactions made a net purchase of 3,696 billion yuan to raise Yingfu Fund (02800) to sell Saisheng Pharmaceutical (06600) for more than 1.5 billion yuan
The Zhitong Finance App learned that on April 2, the Hong Kong Stock Exchange had a net purchase of HK$3,696 billion, of which Hong Kong Stock Connect (Shanghai) had a net purchase of HK$2,184 billion and the Hong Kong Stock Connect (Shenzhen) transaction made a net purchase of HK$1,512 billion. The individual stocks that Beishui Net bought the most were Yingfu Fund (02800), Ideal Automobile-W (02015), and Meituan-W (03690). The individual stocks sold the most by Beishui Net were Saisheng Pharmaceutical (06600) and Xiaopeng Automobile-W (09868). Hong Kong Stock Connect (Shanghai) active trading stocks Hong Kong Stock Connect (Shenzhen) active trading stocks Yingfu Fund (02800) received a net purchase
Changes in Hong Kong stocks | Saisheng Pharmaceutical (06600) resumed trading more than 11%, annual net profit increased by more than 31% year-on-year, and the company received a 17% premium and privatization
Saisheng Pharmaceutical (06600) resumed trading more than 11%. As of press release, it rose 11.35% to HK$17.86, with a turnover of HK$43.194 million.
Saisheng Pharmaceutical announced that it will resume trading on the morning of April 2
Saisheng Pharmaceutical (06600) announced that trading of the company's shares will resume at 9:00 a.m. on April 2, 2024.
SciClone Pharmaceuticals Logs 31% Increase in 2023 Profit
SciClone Pharmaceuticals (Holdings) (HKG:6600) recorded a 31.2% rise in attributable profit for the year ended Dec. 31, 2023, to 1.12 billion yuan from 855.4 million yuan in 2022, a filing posted on t
No Data